Jan Kisielow

Title: Jan Kisielow: Innovator in Chimeric Antigen Receptors

Introduction

Jan Kisielow is a prominent inventor based in Schlieren, Switzerland. He has made significant contributions to the field of immunology through his innovative work on chimeric antigen receptors. With a total of 2 patents, his inventions are paving the way for advancements in targeted therapies.

Latest Patents

Kisielow's latest patents focus on chimeric antigen-receptor polypeptide heterodimers. These inventions comprise two polypeptides, where the first contains an extracellular part of the major histocompatibility complex I alpha chain, and the second contains a 32-microglobulin domain. Alternatively, the first polypeptide may contain an extracellular part of the major histocompatibility complex II alpha chain, while the second contains a major histocompatibility complex II beta chain. One of the polypeptides includes a transmembrane domain, a hinge region, and an intracellular domain of the T cell receptor alpha chain. The other polypeptide contains similar features along with an antigen-peptide covalently linked to the extracellular MHC domain. Additionally, the invention relates to a method for identifying a TCR recognizable peptide sequence using the heterodimer.

Career Highlights

Jan Kisielow is associated with ETH Zurich, a leading research institution known for its cutting-edge scientific advancements. His work has garnered attention in the field of immunology, particularly for its potential applications in cancer therapy and other diseases.

Collaborations

Kisielow has collaborated with notable colleagues, including Manfred Kopf and Franz-Josef Obermair. These partnerships have contributed to the development and refinement of his innovative ideas.

Conclusion

Jan Kisielow's contributions to the field of chimeric antigen receptors exemplify the impact of innovative thinking in medical science. His patents and collaborations continue to influence advancements in targeted therapies.